New Data Reinforce the Clinical Value of the Perceval Sutureless Valve as a Safe & Effective Bioprosthesis for Patients in Ne...
January 27 2017 - 12:00PM
Business Wire
Study Results Unveiled at The Society of Thoracic Surgeons 53rd
Annual Meeting
LivaNova, PLC (NASDAQ:LIVN; LSE:LIVN) (“LivaNova”), a
market-leading medical technology and innovation company, announced
that a data presentation on the PercevalTM sutureless valve was
unveiled at The Society of Thoracic Surgeons 53rd Annual Meeting
(STS), which took place January 21-25, 2017 in Houston. These data
highlight the safety, efficiency, and performance of Perceval, the
first-ever, truly sutureless surgical valve designed for patients
requiring an aortic valve replacement (AVR).
The study, Aortic Valve Replacement With Sutureless Perceval
Bioprosthesis: Single-Center Experience With 617 Implants, analyzed
patients who underwent AVR with the Perceval bioprosthesis. The
study found that AVR procedures conducted with Perceval resulted in
low mortality and excellent hemodynamic performance for patients.
This is the largest single center experience reported with
Perceval.
“As one of the latest solutions in valve replacement surgery,
the Perceval sutureless valve optimizes the overall surgical
approach for surgeons. In the presented analysis, implantation with
Perceval allowed surgeons to perform minimally invasive approaches
with shorter procedure times, specifically reducing the cross-clamp
and cardiopulmonary bypass time, which can lead to faster recovery
times for patients,” said Dr. Marco Solinas, MD, Cardiac Surgeon at
G. Monasterio Tuscany Foundation, Massa, Italy.
The study found that Perceval, with its safe and reproducible
features, allowed surgeons to employ a minimally invasive approach
during AVR procedures. At follow-up at approximately 16 months,
freedom from reoperation was 99% and patient survival was
91.3%.
“These positive results reinforce findings from previous studies
for Perceval1, the only truly sutureless valve designed for
patients requiring surgical aortic valve replacement,” said Brian
Duncan, MD, Vice President, Medical Affairs, Cardiac Surgery at
LivaNova. “With the foundation of advancing technology and
transforming lives, LivaNova is committed to delivering advanced
solutions for cardiac surgery and we look forward to continuing the
expansion of Perceval’s clinical evidence base and its growing use
in the international cardiac surgery community.”
Perceval has been implanted in more than 20,000 patients in over
310 hospitals in 34 countries across the world. To learn more about
Perceval and its patient benefits, please visit
www.heartvalvesurgery.com/sutureless.
About LivaNova
LivaNova PLC, headquartered in London, UK, is a global
medical technology company formed by the merger of Sorin S.p.A, a
leader in the treatment of cardiovascular diseases,
and Cyberonics Inc., a medical device company with core
expertise in neuromodulation. LivaNova transforms medical
innovation into meaningful solutions for the benefit of patients,
healthcare professionals and healthcare systems. The company
employs approximately 4,600 employees worldwide. With a presence in
more than 100 countries, LivaNova operates as three business
franchises: Cardiac Rhythm Management, Cardiac Surgery and
Neuromodulation, with operating headquarters in Clamart (France),
Mirandola (Italy) and Houston (U.S.A.), respectively.
LivaNova is listed on NASDAQ and listed on the Official
List of the UK’s Financial Conduct Authority and traded
on London Stock Exchange (LSE) under the ticker symbol
“LIVN.”
For more information, please visit www.LivaNova.com.
References1 Shrestha et al. Interactive Cardiovascular
and Thoracic Surgery. 2013. 1-5.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170127005544/en/
LivaNova PLC Investor Relations and MediaKaren
King, +1 (281) 228-7262Vice President, Investor Relations &
Corporate CommunicationsorDeanna Wilke, +1 (281)
727-2764Corporate External Communications
Managercorporate.communications@livanova.com
Livanova (LSE:LIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Livanova (LSE:LIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024